Highlights & Accomplishments
-35+ INDs/CTAs (no clinical holds), multiple indications -20+ marketing applications (no refuse to file or complete response letters), multiple indications -More than 60 “best practices” talks at DIA, RAPS, other associations, and law firms -Active in management of Regulatory Affairs, and Clinical Safety and Pharmacovigilance best practices communities -Located near FDA, attend FDA Advisory Committee […]
READ MORE